Transoral laser microsurgery for early glottic cancer as one‐stage single‐modality therapy

Abstract

A study was undertaken to determine the oncologic outcomes in a consecutive series of early glottic carcinomas treated with transoral CO₂ laser microsurgery (TLM) as a one-stage single-modality therapy, without any postoperative radiation therapy or retreatment with laser. We further evaluated correlations between the oncologic outcomes and clinicopathologic factors including tumor location and surgical margin. Retrospective analysis of medical records. The medical records of 118 consecutive patients with early stage (T1, T2) glottic carcinoma who underwent TLM by a single surgeon as an initial treatment from 1997 to 2011 were retrospectively reviewed. The oncologic outcomes were evaluated, and correlations to clinicopathologic factors were analyzed. The 5-year disease-free survival, ultimate local control with laser alone, disease-specific survival, overall survival, and organ preservation rates were 87.9%, 94.2%, 99.0%, 92.2%, and 96.2%, respectively. Neither the reported surgical margin nor the extension of tumor to the anterior commissure, arytenoid, subglottis, and ventricle showed any significant impact on local control or survival. Transoral CO₂ laser microsurgery as one-stage single-modality therapy resulted in a high rate of local control and a high survival rate in selected cases of early glottic carcinoma, regardless of the location of tumor and histopathology report on the surgical margin.